These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Seden K; Back D Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895 [TBL] [Abstract][Full Text] [Related]
25. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. López-Labrador FX; Moya A; Gonzàlez-Candelas F Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527 [TBL] [Abstract][Full Text] [Related]
27. New HCV drugs trigger race for more tolerable therapies. Williams SC Nat Med; 2011 Dec; 17(12):1526. PubMed ID: 22146431 [No Abstract] [Full Text] [Related]
28. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Ghany MG; Nelson DR; Strader DB; Thomas DL; Seeff LB; Hepatology; 2011 Oct; 54(4):1433-44. PubMed ID: 21898493 [No Abstract] [Full Text] [Related]
29. Treatment of hepatitis C 2010: a focus on protease inhibitors. Lemon M S D Med; 2010 Jun; 63(6):214-5. PubMed ID: 20853592 [No Abstract] [Full Text] [Related]
30. HCV protease inhibitors bring new options for patients. Traynor K Am J Health Syst Pharm; 2011 Aug; 68(15):1372, 1374, 1379. PubMed ID: 21785015 [No Abstract] [Full Text] [Related]
31. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752 [TBL] [Abstract][Full Text] [Related]
32. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. Thomson JA; Perni RB Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221 [TBL] [Abstract][Full Text] [Related]
33. Clinical trial investigates two experimental HCV drugs. AIDS Patient Care STDS; 2010 Apr; 24(4):270. PubMed ID: 20402017 [No Abstract] [Full Text] [Related]
34. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Njoroge FG; Chen KX; Shih NY; Piwinski JJ Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821 [TBL] [Abstract][Full Text] [Related]
35. [Telaprevir: new possibilities for antiviral treatment in patients with chronic hepatitis C]. Nikitin IG; Gogova LM; Baikova IE; Kislyakov VA; Volynkina VM Ter Arkh; 2012; 84(11):75-80. PubMed ID: 23252254 [TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560 [TBL] [Abstract][Full Text] [Related]
37. Protease inhibitors in hepatitis C: from chronic disease to cure. Iqbal M; McCormick PA Ir Med J; 2011 Sep; 104(8):230-1. PubMed ID: 22125874 [No Abstract] [Full Text] [Related]
38. [Victrelis and Incivek against hepatitis C: some promising options]. Sabourin G Perspect Infirm; 2012; 9(1):58-9. PubMed ID: 22295460 [No Abstract] [Full Text] [Related]
39. [New treatments for hepatitis C, which targets, what timeline?]. Goossens N; Negro F Rev Med Suisse; 2011 Sep; 7(307):1683-8. PubMed ID: 21987876 [TBL] [Abstract][Full Text] [Related]
40. Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy. Hofmann WP; Zeuzem S Nat Rev Gastroenterol Hepatol; 2011 Dec; 9(2):67-8. PubMed ID: 22183183 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]